US ETFDetailed Quotes

COYA Coya Therapeutics

Watchlist
  • 7.040
  • -0.190-2.63%
Close Nov 1 16:00 ET
  • 6.897
  • -0.143-2.04%
Post 20:02 ET
116.87MMarket Cap-9513P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Sep 16 07:16
    Update
    $Coya Therapeutics (COYA.US)$ Reuters· 1 min ago
    Coya Therapeutics Announces Subcutaneously Administered Coya 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
    Jaguar8
    Jaguar8
    Sep 16 07:15
    NEWS
    $Coya Therapeutics (COYA.US)$
    Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
    Coya Therapeutics (NASDAQ: COYA) announces promising results for COYA 302, a subcutaneously administered anti-inflammatory biologic, in a preclinical Parkinson's disease (PD) mouse model. The study shows that COYA 302significantly reduces neuroinflammation in key brain regions affected b...
    Jaguar8
    Jaguar8
    Aug 2 11:08
    NEWS
    $Coya Therapeutics (COYA.US)$
    Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
    Coya Therapeutics (NASDAQ: COYA) has announced that results from a double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease will be presented at the Clinical Trials on...
    Jaguar8
    Jaguar8
    Jul 31 21:03
    NEWS TODAY
    $Coya Therapeutics (COYA.US)$
    Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
    Coya Therapeutics (NASDAQ: COYA) has filed for intellectual property protectionfor the combination of COYA 301 (low-dose interleukin-2) and Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs).
    This combination aims to enhance regulatory T cell function and may offer a mul...
    Trytosaveabit
    Trytosaveabit
    Jul 15 05:20
    Update
    $Coya Therapeutics (COYA.US)$ Reuters· just
    Coya Therapeutics : Got Notification From FDA Stating That Additional Non-Clinical Data Is Required Prior to Initiation of Coya 302 ALS Study
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data